Pipeline

DrugIndicationsPreclinicalINDPhase 1Phase 2Phase 3
Prexigebersen
BP1001
AML

BP1001-A
Solid Tumors e.g. ovary, endometrium

BP1002
Liposomal Bcl-2
CLL, Lymphoma

BP1002
Liposomal Bcl-2
Refractory/relapsed AML (Including those who have relapsed after Bcl-2 inhibitor treatment)

BP1003
Liposomal STAT3
Solid Tumors (e.g. pancreas, lung)

DrugIndicationStage
Prexigebersen
BP1001
AMLPhase 2
BP1001-A
Solid Tumors e.g. ovary, endometriumPhase 1
BP1002
Liposomal Bcl-2
CLL, LymphomaPhase 1
BP1002
Liposomal Bcl-2
Refractory/relapsed AML (Including those who have relapsed after Bcl-2 inhibitor treatment)Phase 1
BP1003
Liposomal STAT3
Solid Tumors (e.g. pancreas, lung)IND